Ralph Niven Aerovate Therapeutics, Inc. (AVTE) insider trading activity

Ralph Niven is CHIEF SCIENTIFIC OFFICER of Aerovate Therapeutics, Inc.. Currently has a direct ownership of 1,609 shares of AVTE, which is worth approximately $3,974. The most recent transaction as insider was on Nov 07, 2022, when has been sold 2,250 shares (Common Stock) at a price of $1.94 per share, resulting in proceeds of $4,365. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.61K

0% 3M change

0% 12M change

Total Value Held $3,974

RALPH NIVEN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 07 2022	BUY Exercise of conversion of derivative security	$4,365 $1.94 p/Share	2,250 Added 36.83%	3,859 Common Stock
Oct 05 2022	SELL Open market or private sale	$35,933 $15.97 p/Share	2,250 Reduced 58.31%	1,609 Common Stock
Oct 05 2022	BUY Exercise of conversion of derivative security	$4,365 $1.94 p/Share	2,250 Added 36.83%	3,859 Common Stock
Sep 06 2022	SELL Open market or private sale	$42,750 $19.0 p/Share	2,250 Reduced 58.31%	1,609 Common Stock
Sep 06 2022	BUY Exercise of conversion of derivative security	$4,365 $1.94 p/Share	2,250 Added 36.83%	3,859 Common Stock
Aug 18 2022	SELL Open market or private sale	$47,655 $21.18 p/Share	2,250 Reduced 58.31%	1,609 Common Stock
Aug 18 2022	BUY Exercise of conversion of derivative security	$4,365 $1.94 p/Share	2,250 Added 36.83%	3,859 Common Stock

Ralph Niven

CHIEF SCIENTIFIC OFFICER

Waltham,, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AVTE shares.

Notify only if

Value

Insider Trading

Get notified when an Aerovate Therapeutics, Inc. insider buys or sells AVTE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aerovate Therapeutics, Inc.

Track Activities on AVTE

Account